Biogen Inc (NASDAQ:BIIB) has been given an “A” credit rating by analysts at Morningstar. The research firm’s “A” rating indicates that the company is a low default risk. They also gave their stock a five star rating.

In related news, CMO Alfred Sandrock sold 441 shares of the firm’s stock in a transaction on Friday, December 4th. The shares were sold at an average price of $277.00, for a total transaction of $122,157.00. Following the completion of the transaction, the chief marketing officer now directly owns 7,740 shares of the company’s stock, valued at $2,143,980. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Other hedge funds and institutional investors recently added to or reduced their stakes in the company. Harvest Management bought a new position in Biogen during the third quarter valued at approximately $292,000. Meag Munich Ergo Kapitalanlagegesellschaft boosted its stake in shares of Biogen by 66.7% in the third quarter. Meag Munich Ergo Kapitalanlagegesellschaft now owns 2,500 shares of the biotechnology company’s stock valued at $722,000 after buying an additional 1,000 shares during the period. Chelsea Counsel Company increased its stake in Biogen by 108.7% in the third quarter. Chelsea Counsel Company now owns 4,800 shares of the biotechnology company’s stock worth $1,401,000 after buying an additional 2,500 shares in the last quarter. Saturna Capital increased its stake in Biogen by 62.2% in the third quarter. Saturna Capital now owns 4,886 shares of the biotechnology company’s stock worth $1,426,000 after buying an additional 1,874 shares in the last quarter. Finally, MUFG Americas increased its stake in Biogen by 1.8% in the third quarter. MUFG Americas now owns 14,396 shares of the biotechnology company’s stock worth $4,201,000 after buying an additional 256 shares in the last quarter.

Several other equities research analysts have also issued reports on the company. Zacks Investment Research raised Biogen from a “hold” rating to a “buy” rating and set a $310.00 target price for the company in a research report on Monday, October 26th. Vetr raised Biogen from a “buy” rating to a “strong-buy” rating and set a $346.23 target price for the company in a research report on Tuesday, December 29th. Jefferies Group reaffirmed a “buy” rating and set a $322.00 target price (down from $348.00) on shares of Biogen in a research report on Thursday, October 15th. JPMorgan Chase & Co. reaffirmed an “overweight” rating and set a $414.00 target price on shares of Biogen in a research report on Tuesday, October 20th. Finally, Raymond James reaffirmed a “strong-buy” rating and set a $404.00 target price on shares of Biogen in a research report on Tuesday, October 13th. Nine research analysts have rated the stock with a hold rating and twenty have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $375.29.

Biogen (NASDAQ:BIIB) opened at 273.06 on Friday. The stock has a market capitalization of $60.18 billion and a PE ratio of 17.80. The stock’s 50 day moving average price is $285.04 and its 200 day moving average price is $298.99. Biogen has a 1-year low of $254.00 and a 1-year high of $480.18.

Biogen (NASDAQ:BIIB) last announced its quarterly earnings data on Wednesday, January 27th. The biotechnology company reported $4.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.08 by $0.42. The company had revenue of $2.84 billion for the quarter, compared to analysts’ expectations of $2.70 billion. During the same period last year, the business earned $4.09 earnings per share. The company’s quarterly revenue was up 7.5% compared to the same quarter last year. On average, equities research analysts predict that Biogen will post $18.50 earnings per share for the current fiscal year.

Biogen Inc., formerly Biogen Idec Inc., is a global biopharmaceutical company. The Company is focused on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders. The Company develops, manufactures and markets products designed for the treatment of multiple sclerosis (NASDAQ:BIIB) and hemophilia A and B. The Company’s marketed products include AVONEX, PLEGRIDY, TECFIDERA, TYSABRI, FAMPYRA for multiple sclerosis (MS), ALPROLIX for hemophilia B, and ELOCTATE for hemophilia A, among others. It also collaborates on the development and commercialization of RITUXAN (rituximab), which is a monoclonal antibody for the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia and other conditions and share profits and losses for GAZYVA, which is for the treatment of chronic lymphocytic leukemia.

12 Month Chart for NASDAQ:BIIB

To view more credit ratings from Morningstar, visit www.jdoqocy.comclick-7674909-10651170.

Receive News & Ratings for Biogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen Inc and related companies with MarketBeat.com's FREE daily email newsletter.